Treatment of Depression-Related Loss of Libido
Treat the underlying depression with either cognitive behavioral therapy (CBT) or a second-generation antidepressant, specifically choosing bupropion, mirtazapine, or agomelatine as first-line pharmacotherapy to simultaneously address both depression and preserve sexual function. 1
Treatment Algorithm
Step 1: Treat the Depression Itself
The primary intervention must address the depression, as untreated depression directly causes diminished libido through its effects on mood, energy, and sexual desire 2. The 2016 American College of Physicians guideline establishes that CBT and second-generation antidepressants have equivalent efficacy for major depressive disorder 1.
Key decision point: Choose between:
- Cognitive Behavioral Therapy (CBT) - if patient prefers non-pharmacologic approach, has access to qualified therapist, and depression severity allows
- Pharmacotherapy - if patient prefers medication, lacks access to therapy, or has severe depression requiring faster intervention
Step 2: Select the Right Antidepressant
If choosing pharmacotherapy, antidepressant selection is critical because most antidepressants worsen sexual dysfunction 2.
First-line antidepressants with favorable sexual profiles:
Bupropion - Most evidence for preserving sexual function; works through dopaminergic mechanisms rather than serotonergic 3, 4, 5
Mirtazapine - Lower rates of sexual dysfunction than SSRIs 3, 4
Avoid as first-line:
- SSRIs (fluoxetine, paroxetine, sertraline) - cause sexual dysfunction in up to 70% of patients 7
- SNRIs - similar high rates of sexual side effects 4
Step 3: Monitor and Adjust
At 4-6 weeks: Assess both depressive symptoms AND sexual function using validated scales (PHQ-9 for depression) 1.
If depression improves but sexual dysfunction persists or worsens:
The guidelines acknowledge this paradox: antidepressants treat depression (which improves libido) but simultaneously cause sexual dysfunction as a side effect 2. This creates a clinical dilemma requiring intervention.
Step 4: Management of Antidepressant-Induced Sexual Dysfunction
If sexual dysfunction emerges on treatment:
Switch antidepressants - Change to bupropion, mirtazapine, or agomelatine if not already using 5, 8
Augmentation strategies:
Critical Clinical Considerations
Common pitfall: Assuming all sexual dysfunction is from the antidepressant. Depression itself causes loss of libido in 23-50% of men and 33-90% of women 7. Baseline sexual function must be documented before starting treatment 3, 4.
The endocrinology connection: While the AACE guidelines emphasize checking testosterone and prolactin levels 2, this is secondary to treating the depression itself. Depression-related libido loss occurs even with normal hormone levels through central nervous system mechanisms.
Relationship dynamics: The guidelines emphasize evaluating the couple together when possible, as relationship factors independently affect sexual function 2. Address these concurrently with depression treatment.
Treatment phases: Depression treatment requires 6-12 weeks for acute phase, then 4-9 months continuation 1. Sexual function should improve as depression remits, typically within the first 6-12 weeks if the right antidepressant is chosen.
Evidence Quality Note
The 2016 ACP guideline 1 provides the strongest, most recent evidence for depression treatment selection (moderate-quality evidence, strong recommendation). The sexual dysfunction management strategies have lower-quality evidence 4, 5, but clinical consensus strongly supports antidepressant selection based on sexual side effect profiles when treating patients with pre-existing sexual concerns.